Magnetar Financial LLC Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Magnetar Financial LLC decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 20,113 shares of the biopharmaceutical company’s stock after selling 1,964 shares during the quarter. Magnetar Financial LLC’s holdings in Amicus Therapeutics were worth $189,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. grew its stake in Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock valued at $2,381,000 after acquiring an additional 75,807 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $834,000. Massachusetts Financial Services Co. MA lifted its position in Amicus Therapeutics by 4.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after buying an additional 139,491 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after buying an additional 242,672 shares during the last quarter. Finally, Algert Global LLC grew its holdings in Amicus Therapeutics by 192.6% in the 3rd quarter. Algert Global LLC now owns 259,160 shares of the biopharmaceutical company’s stock valued at $2,768,000 after buying an additional 170,575 shares in the last quarter.

Amicus Therapeutics Stock Down 0.8 %

NASDAQ:FOLD opened at $9.01 on Monday. Amicus Therapeutics, Inc. has a 52 week low of $8.55 and a 52 week high of $12.65. The stock’s fifty day moving average is $9.35 and its two-hundred day moving average is $10.06. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -50.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Analysts Set New Price Targets

FOLD has been the topic of several analyst reports. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.